Clinical Trials Logo
  1. Home
  2. Dry Eye Syndrome
  3. NCT05245604
  4. Details
NCT05245604 Clinical Trial

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Dry Eye Syndrome Clinical Trial

Official title:
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Study of TJO-087 for Evaluating 32 Weeks Safety and Efficacy in Moderate to Severe Dry Eye Disease Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05245604
Other study ID # TJO-087-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 19, 2020
Est. completion date April 2023

Study information
Verified date February 2022
Source Taejoon Pharmaceutical Co., Ltd.
Contact Sukyoung Kwon
Phone 82-2-799-0184
Email skkwon@taejoon.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.

Recruitment information / eligibility
Status Recruiting
Enrollment 182
Est. completion date April 2023
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Male or female, age 20 or over - Patients with moderate to severe dry eye - Screening both eyes, the corrected visual acuity is 0.2 or more - Written informed consent to participate in the trial Exclusion Criteria: - Screening visits within 2 weeks who treated with topical NSAIDs/hyaluronate sodium ophthalmic solutions - Screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease) - Intraocular pressure(IOP)> 25 mmHg - Patient using or to use punctual plug within 1 months. - Patients with contact lens.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• TJO-087
Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
• Cyclosporine ophthalmic solution 0.05%
Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day

Locations
Country Name City State
Korea, Republic of Hyo Myung, Kim Seoul

Sponsors (1)
Lead Sponsor Collaborator
Taejoon Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change From Baseline in Non-anesthetic Schirmer Test at Week 32 The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac. Baseline and Week 32
Secondary Change From Baseline in Non-anesthetic Schirmer Test at Week 8, 16, 24 The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac. Baseline, Week 8, 16 and 24
Secondary Change From Baseline in Corneal Fluorescein Staining Score at Week 8, 16, 24 and 32 Change from Baseline in corneal staining of the worse eye using blue fluorescein staining procedure. Baseline, Week 8, 16, 24 and 32
See also
  Status Clinical Trial Phase
Completed NCT02597803 - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Phase 2/Phase 3
Completed NCT02522312 - A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients N/A
Completed NCT01863368 - Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining N/A
Completed NCT01753752 - Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation Phase 2
Completed NCT01753687 - Correlation of Different Signs for Assessment of Dry Eye Syndrome N/A
Completed NCT01198782 - Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Phase 4
Completed NCT01212471 - A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease Phase 3
Completed NCT01162954 - Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Phase 1
Completed NCT00544713 - Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery N/A
Completed NCT00535054 - Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms N/A
Completed NCT00344721 - A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome N/A
Completed NCT03830359 - Efficacy, Safety of T2769 in Dry Eye Disease N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Completed NCT02758327 - Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Phase 4
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Completed NCT01970917 - Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Phase 4
Completed NCT02092207 - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome Phase 2
Completed NCT01541891 - Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome Phase 2
Completed NCT01252121 - Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline N/A
Completed NCT00765804 - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye Phase 2